Overview

A Study to Test How Well Healthy Men Tolerate Different Doses of BI 764198

Status:
Completed
Trial end date:
2020-10-08
Target enrollment:
Participant gender:
Summary
To investigate safety and tolerability of BI 764198 in healthy male subjects following oral administration of multiple rising doses per day over 14 days and to explore the pharmacokinetics (PK) of BI 764198 after single and multiple oral dosing. In addition, the effect of BI 764198 on the pharmacokinetics of midazolam, given as an oral microdose, will be explored after multiple oral dosing.
Phase:
Phase 1
Details
Lead Sponsor:
Boehringer Ingelheim